Progress Update: CTRN International Sites

Progress update by Dr. Rabi Tawil

The primary objective of this grant is to expand the ReSolve Study to include two European sites. The purpose of the ReSolve was to study and validate clinical measures for future clinical trials. The inclusion of the two European sites allows the ReSolve Study to boost the number of study subjects from 160 to 210. The increased number will allow us to obtain more robust and accurate data regarding the best clinical outcome measures to be used in clinical trials. Having outcome measures that are validated is critical in all future FSHD clinical trials as they increase the chance that effective treatments are approved by the FDA. Despite the COVID19 pandemic and the addition of 24 month visit, the European sites more than met their expected target recruitment, adding a total of 50 subjects to the ReSolve study.

See grant CTRN International Sites.